Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
transforming growth factor beta 3 + dexamethasone sodium phosphate
- Development stage
- Unknown
- Lead developer
- TheiaNova
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Ophthalmic
01
Overview
TN-001 is a topical ophthalmic drug candidate being developed by TheiaNova for the treatment of progressive keratoconus. It is a combination of two active ingredients: recombinant human transforming growth factor beta-3 (TGF-β3) and dexamethasone sodium phosphate. The therapy works by transiently activating developmental pathways to induce corneal keratocytes to re-express embryonic collagen phenotypes and secrete new collagen. This regenerative process is intended to restore the biomechanical strength of the corneal stroma, thereby halting the progression of keratoconus. TN-001 is currently being evaluated in a Phase 1/2 clinical trial (NCT07388069) in Australia.
- Other names
- TGF-beta 3 + dexamethasone sodium phosphate
02
Targets
GR (Glucocorticoid receptor)TGFBR1TGFBR (TGF-beta receptor)
Beyond the preview
Go deeper on transforming growth factor beta 3 + dexamethasone sodium phosphate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on transforming growth factor beta 3 + dexamethasone sodium phosphate.